INSMED Inc 8K

Insmed reported 12‑month interim open‑label extension data showing sustained efficacy and tolerability for investigational PAH therapy TPIP and announced plans to advance a broad Phase 3 registrational program across multiple pulmonary indications.

On July 16, 2026, Insmed Inc. released Exhibit 99.2 summarizing 12‑month interim results from its ongoing 24‑month open‑label extension study of TPIP (treprostinil palmitil inhalation powder) in pulmonary arterial hypertension (PAH) patients who rolled over from earlier Phase 2 studies, reporting that 91% of enrolled patients remained on TPIP at Month 12, the drug continued to show a generally favorable safety and tolerability profile with no new safety signals and only mild-to-moderate cough, and patients demonstrated sustained improvements in six‑minute walk distance, NT‑proBNP, WHO functional class, and REVEAL Lite 2.0 mortality‑risk scores for both those who continued TPIP and those who crossed over from placebo; the company framed these data as supporting TPIP’s potential best‑in‑class profile and outlined plans for an expansive Phase 3 registrational program across PAH, PH‑ILD, IPF, and PPF.

Filing Facts

CIK

1104506

Ticker

INSM

Form

8K

Source Type

fda

Accession

0001140361-26-028602

Alert Tier

6